Kim, Woori
Tripathi, Mohit
Kim, Chunhyung
Vardhineni, Satyapavan
Cha, Young http://orcid.org/0000-0001-7647-0699
Kandi, Shamseer Kulangara
Feitosa, Melissa
Kholiya, Rohit
Sah, Eric http://orcid.org/0000-0001-7522-2036
Thakur, Anuj
Kim, Yehan
Ko, Sanghyeok
Bhatia, Kaiya
Manohar, Sunny
Kong, Young-Bin
Sindhu, Gagandeep
Kim, Yoon-Seong http://orcid.org/0000-0001-6246-5477
Cohen, Bruce http://orcid.org/0000-0002-8861-6285
Rawat, Diwan S. http://orcid.org/0000-0002-5473-7476
Kim, Kwang-Soo http://orcid.org/0000-0002-6081-9857
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (NS127391, OD024622)
U.S. Department of Health & Human Services | National Institutes of Health
DST | Science and Engineering Research Board (EMR/2014/001127)
Article History
Received: 29 December 2022
Accepted: 5 July 2023
First Online: 18 July 2023
Competing interests
: W.K., M.T., S.V., S.K.K., R.K., A.T., D.S.R., and K.-S.K. are co-inventors of a pending U.S. utility patent application no. 18/013,155 that is assigned to the McLean Hospital Corporation and the University of Delhi. The patent application no. 18/013,155 describes and claims compounds including SPV-94 (4A7C-301) that are described in this manuscript and methods of using these compounds to treat neurodegenerative diseases. K.-S.K. is a co-founder of NurrOn Pharmaceutical, Inc., which has rights to develop compounds disclosed in this manuscript under a licensing agreement with The McLean Hospital Corporation. The remaining authors have no conflicts of interest.